237 related articles for article (PubMed ID: 21245850)
1. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.
Klutz K; Schaffert D; Willhauck MJ; Grünwald GK; Haase R; Wunderlich N; Zach C; Gildehaus FJ; Senekowitsch-Schmidtke R; Göke B; Wagner E; Ogris M; Spitzweg C
Mol Ther; 2011 Apr; 19(4):676-85. PubMed ID: 21245850
[TBL] [Abstract][Full Text] [Related]
2. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.
Klutz K; Willhauck MJ; Dohmen C; Wunderlich N; Knoop K; Zach C; Senekowitsch-Schmidtke R; Gildehaus FJ; Ziegler S; Fürst S; Göke B; Wagner E; Ogris M; Spitzweg C
Hum Gene Ther; 2011 Dec; 22(12):1563-74. PubMed ID: 21851208
[TBL] [Abstract][Full Text] [Related]
3. Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes.
Urnauer S; Klutz K; Grünwald GK; Morys S; Schwenk N; Zach C; Gildehaus FJ; Rödl W; Ogris M; Wagner E; Spitzweg C
J Gene Med; 2017 May; 19(5):. PubMed ID: 28423213
[TBL] [Abstract][Full Text] [Related]
4. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
5. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
[TBL] [Abstract][Full Text] [Related]
6. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
[TBL] [Abstract][Full Text] [Related]
7. Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.
Urnauer S; Morys S; Krhac Levacic A; Müller AM; Schug C; Schmohl KA; Schwenk N; Zach C; Carlsen J; Bartenstein P; Wagner E; Spitzweg C
Mol Ther; 2016 Aug; 24(8):1395-404. PubMed ID: 27157666
[TBL] [Abstract][Full Text] [Related]
8. EGFR-targeted nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer metastases.
Urnauer S; Müller AM; Schug C; Schmohl KA; Tutter M; Schwenk N; Rödl W; Morys S; Ingrisch M; Bertram J; Bartenstein P; Clevert DA; Wagner E; Spitzweg C
Oncotarget; 2017 Nov; 8(54):92195-92208. PubMed ID: 29190908
[TBL] [Abstract][Full Text] [Related]
9. Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.
Klutz K; Willhauck MJ; Wunderlich N; Zach C; Anton M; Senekowitsch-Schmidtke R; Göke B; Spitzweg C
Hum Gene Ther; 2011 Nov; 22(11):1403-12. PubMed ID: 21488714
[TBL] [Abstract][Full Text] [Related]
10. Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma.
Knoop K; Schwenk N; Dolp P; Willhauck MJ; Zischek C; Zach C; Hacker M; Göke B; Wagner E; Nelson PJ; Spitzweg C
Hum Gene Ther; 2013 Mar; 24(3):306-16. PubMed ID: 23402366
[TBL] [Abstract][Full Text] [Related]
11. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
12. Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (
Schug C; Kitzberger C; Sievert W; Spellerberg R; Tutter M; Schmohl KA; Eberlein B; Biedermann T; Steiger K; Zach C; Schwaiger M; Multhoff G; Wagner E; Nelson PJ; Spitzweg C
Clin Cancer Res; 2019 Oct; 25(19):5997-6008. PubMed ID: 31196853
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeted NIS polyplexes-a theranostic strategy toward tumors with heterogeneous receptor expression.
Urnauer S; Schmohl KA; Tutter M; Schug C; Schwenk N; Morys S; Ziegler S; Bartenstein P; Clevert DA; Wagner E; Spitzweg C
Gene Ther; 2019 Apr; 26(3-4):93-108. PubMed ID: 30683895
[TBL] [Abstract][Full Text] [Related]
14. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation.
Schäfer A; Pahnke A; Schaffert D; van Weerden WM; de Ridder CM; Rödl W; Vetter A; Spitzweg C; Kraaij R; Wagner E; Ogris M
Hum Gene Ther; 2011 Dec; 22(12):1463-73. PubMed ID: 21644815
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene.
Knoop K; Schwenk N; Schmohl K; Müller A; Zach C; Cyran C; Carlsen J; Böning G; Bartenstein P; Göke B; Wagner E; Nelson PJ; Spitzweg C
J Nucl Med; 2015 Apr; 56(4):600-6. PubMed ID: 25745085
[TBL] [Abstract][Full Text] [Related]
16. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery.
Knoop K; Kolokythas M; Klutz K; Willhauck MJ; Wunderlich N; Draganovici D; Zach C; Gildehaus FJ; Böning G; Göke B; Wagner E; Nelson PJ; Spitzweg C
Mol Ther; 2011 Sep; 19(9):1704-13. PubMed ID: 21587211
[TBL] [Abstract][Full Text] [Related]
17. TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer.
Schug C; Urnauer S; Jaeckel C; Schmohl KA; Tutter M; Steiger K; Schwenk N; Schwaiger M; Wagner E; Nelson PJ; Spitzweg C
Endocr Relat Cancer; 2019 Jan; 26(1):89-101. PubMed ID: 30121623
[TBL] [Abstract][Full Text] [Related]
18. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (
Tutter M; Schug C; Schmohl KA; Urnauer S; Schwenk N; Petrini M; Lokerse WJM; Zach C; Ziegler S; Bartenstein P; Weber WA; Wagner E; Lindner LH; Nelson PJ; Spitzweg C
Theranostics; 2020; 10(10):4490-4506. PubMed ID: 32292510
[No Abstract] [Full Text] [Related]
19. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.
Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726
[TBL] [Abstract][Full Text] [Related]
20. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
